Category

PFE Stock News

Biotechnology

Forget Allergan – Here's Pfizer's Real High-Profit Ace

Big-cap investors were profoundly underwhelmed when the Obama administration caused Pfizer Inc. to cancel a $150 billion buyout of another massive pharma, Allergan Plc.

Like most deal-making at this level, there was a lot at stake. Allergan has a portfolio packed with name-brand drugs with long patent lives and a robust generics business. What's more, the deal would have allowed Pfizer to relocate its headquarters to the (extremely) tax-friendly Republic of Ireland and save a ton on payments to Uncle Sam.

Now, normally when a deal like this falls through, the shares take a serious pounding, but the smart money is holding its nerve. In fact, the stock is up just over 10% year to date. That says a lot.

Those investors, along with folks who buy in right now, stand to be richly rewarded in the future.

That's because there's something bigger - much bigger - than the $150 billion Allergan deal coming down the road...

Biotechnology

Pfizer (NYSE: PFE) Stock Price Predictions Look Bullish After $160 Billion Merger

Pfizer Inc. (NYSE: PFE) and competitor Allergan Plc. (NYSE: AGN) announced the largest healthcare deal in history today (Monday).

The combination is a very bullish catalyst for the PFE stock price.

Here's why...

Stocks

Pfizer Stock Price Will Climb After Merger Despite U.S. Treasury Efforts

The Pfizer stock price is up 0.5% today as the U.S. drug giant remains in advanced stages to buy Allergan Plc. (NYSE: AGN).

Pfizer Inc. (NYSE: PFE) is pushing forward with the deal despite the best wishes of the U.S. Treasury, which is trying to curb such mergers.

Here's why...

Top News

Merck, Pfizer Earnings Send Shares in Opposite Directions (NYSE: PFE) (NYSE: MRK)

The Pfizer earnings and Merck earnings reports were both released this morning (Tuesday), and investors are acting differently to these major pharmaceutical stocks.

Pfizer Inc. (NYSE: PFE) stock was up 1.3% in early trading despite missing earnings per share estimates. Merck shares were down 2% despite topping estimates.

Here's why the stocks are behaving so differently...